Gurubaba Pharmax Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 264.70%
- Ebitda 3982.31%
- Net Worth 355.04%
- Total Assets 195.80%
About Gurubaba Pharmax
Gurubaba Pharmax Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 March 2017 (Seven years and ten months 29 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Deepak Krishnani and Rama Krishnani serve as directors at the Company.
Company Details
-
Location
Nagpur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U52200MH2017PTC292286
-
Company No.
292286
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Mar 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Gurubaba Pharmax Private Limited offer?
Gurubaba Pharmax Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antiviral Drugs, Digestive System Drugs & Medicines, Antacid Drugs, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Brain & Nervous System Drugs, Psychotherapeutic Agents, Sexual Wellness Products, Erectile Dysfunction Medicine.
Who are the key members and board of directors at Gurubaba Pharmax?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Krishnani
|
Director | 10-Mar-2017 | Current |
|
Rama Krishnani
|
Director | 10-Mar-2017 | Current |
Financial Performance of Gurubaba Pharmax.
Gurubaba Pharmax Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 264.7% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 355.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gurubaba Pharmax?
In 2020, Gurubaba Pharmax had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gurubaba Pharmax?
Unlock and access historical data on people associated with Gurubaba Pharmax, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gurubaba Pharmax, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gurubaba Pharmax's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
